N
ADMA icon

Natixis’s ADMA Biologics ADMA Stock Holding History

Natixis’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,387
Closed -$80K – 1096
2025
Q4 		$80K Buy
4,387
+3,091
+239% +$52.1K ﹤0.01% 979
2025
Q3 		$19K Sell
1,296
-12,264
-90% -$210K ﹤0.01% 969
2025
Q2 		$247K Sell
13,560
-6,229
-31% -$127K ﹤0.01% 780
2025
Q1 		$379K Buy
+19,789
New +$342K ﹤0.01% 687
2021
Q3 		– Sell
-37,200
Closed -$60K – 1183
2021
Q2 		$60K Buy
+37,200
New +$65.5K ﹤0.01% 841

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Natixis's ADMA Position: Q1 2026 in Review

Natixis sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 4,387 shares — an estimated $80K sold.

Natixis first reported a position in ADMA in Q2 2021 and held it in 5 quarters. The position peaked at $379K in Q1 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Natixis reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 4,387 ADMA Biologics shares in Q1 2026, an estimated $80K.
  • Natixis first reported a position in ADMA Biologics in Q2 2021 and held it in 5 quarters.
  • Natixis's ADMA Biologics position peaked at $379K in Q1 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.